Shukra Medtech Q2 FY27 Revenue Surges 652% to ₹44.20 Cr; Net Profit Jumps to ₹16.01 Cr
Shukra Medtech reported Q2 FY27 standalone revenue of ₹44.20 crore, up 652% YoY. Net profit surged to ₹16.01 crore from ₹2.38 crore. For H1 FY27, revenue was ₹67.73 crore (up 501% YoY) and net profit was ₹31.04 crore. Management highlighted growth driven by exports and focus on scaling the MedTech business.
The substantial percentage increase in revenue and profit, coupled with the positive EBITDA turnaround and strategic commentary on export growth and MedTech expansion, suggests a significant positive impact on the company's financial health and future prospects.
The company reported significant year-on-year growth in revenue and net profit for both the quarter and half-year, along with a positive turn in EBITDA, indicating strong financial performance.
Shukra Medtech Limited (formerly Shukra Pharmaceuticals Limited) announced its unaudited standalone financial results for the quarter and six months ended 30 September 2026.
For the second quarter of FY27, the company reported a standalone revenue from operations of ₹44.20 crore, a significant increase of 652% compared to ₹5.88 crore in Q2 FY26. EBITDA turned positive at ₹22.01 crore, with a margin of 49.8%, a substantial improvement from the negative EBITDA of ₹0.42 crore in the previous year's corresponding quarter. Profit before tax rose to ₹21.13 crore from ₹0.20 crore, and net profit surged to ₹16.01 crore from ₹2.38 crore, marking a 573% year-on-year growth.
The pharmaceutical business reported segment income of ₹32.27 crore, while the MedTech segment contributed ₹12.51 crore to the standalone revenue.
For the first half of FY27, standalone revenue from operations stood at ₹67.73 crore, up 501% from ₹11.27 crore in H1 FY26. EBITDA for the half-year was ₹43.22 crore, with an EBITDA margin of 63.8%. Profit before tax was ₹41.37 crore, and net profit increased to ₹31.04 crore from ₹3.41 crore in H1 FY26.
Mr. Dakshesh Shah, Chairman and Managing Director, highlighted the transformation of the company, driven by a significant increase in exports, which now account for the bulk of growth. He emphasized the need for discipline in quality and managing longer receivable cycles associated with international trade. The company's priority is to make this export business repeatable and to scale the MedTech arm, which is crucial for long-term growth. He also mentioned strengthening pharmaceutical operations alongside building the MedTech platform.
What to do with a filing like this
Shukra Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shukra Pharmaceuticals Limited. Read the original for the full detail.